Prototype FelV isolates for use in disease models and vaccines
AssigneesColorado State University Research Foundation, Harvard University
InventorsEdward A. Hoover, James I. Mullins
Life of this patent
Estimating the term…
Abstract
Molecular clones of feline leukemia virus isolates that encode (a) a prototype highly infectious, minimally pathogenic virus, (b) a variant genome that is replication-defective and associated with a fatal immunodeficiency in cats similar to AIDS (FAIDS) or (c) a chimeric genome that is replication-competent and induces FAIDS. These molecular clones may be used to generate cell lines producing infectious virus which is useful in the preparation of vaccines or in the generation of viremia or disease challenge systems.
Claims25
A method of producing a FeLV vaccine, comprising:
- transfecting a mammalian host cell with a recombinant plasmid capable of directing the expression of the proviral genome of a FeLV-A subtype, said plasmid comprising a DNA sequence encoding the proviral genome of a FeLV-A subtype;
- growing said host cell in an appropriate medium;
- harvesting the FeLV-A subtype;
- and
- inactivating the FeLV-A subtype.
A method of producing a FeLV vaccine, comprising:
- cotransfecting a mammalian host cell with a recombinant plasmid capable of directing the expression of the proviral genome of a FeLV-A subtype, said plasmid comprising a DNA sequence derived from the clone 61C or a naturally occurring variant thereof, and a DNA sequence derived from a FeLV-A clone which is replication competent;
- growing said host cell in an appropriate medium;
- harvesting the FeLV-A subtype;
- and
- inactivating the FeLV-A subtype.
A method of producing a FeLV vaccine, comprising:
- infecting a mammalian host cell with a replication competent virus of the FeLV-A subtype;
- growing said host cell in an appropriate medium;
- harvesting the FeLV-A subtype;
- and
- inactivating the FeLV-A subtype.
A method for protecting a feline host from FeLV infection, comprising:
- administering to a feline host an immunogenically effective amount of a composition comprising an inactivated FeLV-A subtype in combination with a physiologically acceptable carrier or diluent.
A vaccine against FeLV-induced disease, comprising an inactivated FeLV-A subtype in combination with a suitable adjuvant.
A vaccine against FeLV-induced disease, comprising a FeLV-A subtype encoded by a DNA sequence derived from clone 61E or a naturally occurring variant thereof, in combination with a FeLV-A subtype encoded by a DNA sequence derived from clone 61C or a naturally occurring variant thereof, and a physiologically acceptable carrier or diluent.
Dependencies are inferred from the claim text.